clinical trial

April 25, 2017

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group

Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the third cohort of its Phase 1 melanoma trial (NCT02676869), ... Read more

April 6, 2017

Opdivo, Yervoy Combo Improved Survival in Advanced Melanoma Phase 3 Trial

News

Opdivo (nivolumab) in combination with Yervoy (ipilimumab), as well as Opdivo alone, outperformed Yervoy monotherapy in terms of overall survival in a Phase 3 clinical trial of previously untreated ... Read more

February 9, 2017February 9, 2017

Keytruda Benefits Patients with Rare Mucosal Melanoma, Trials Show

News

Updates from clinical trials of Keytruda (pembrolizumab) for melanoma show that besides its known benefits for people with typical melanoma, the treatment is also effective against mucosal melanoma — a ... Read more

November 1, 2016November 1, 2016

Promising Clinical Data from Melanoma Combination Therapy to Be Presented at Upcoming Meeting

News

Array BioPharma and Pierre Fabre will present data from the COLUMBUS Phase 3 clinical trial showing that melanoma patients with BRAF mutations may benefit more from the combination of encorafenib ... Read more

July 28, 2016July 28, 2016

Metastatic Melanomas Respond to Immunotherapy Combo in Early Clinical Study

News

The immune-therapy drug ipilimumab together with talimogene laherparepvec, or T-VEC, produced positive results in a Phase 1b clinical trial in patients with metastatic melanomas, who did not respond to ... Read more

July 21, 2016July 21, 2016

Immunotherapy Approach to Treat Melanoma Looks Promising, Studies Reveal

News

Blocking immune checkpoints as well as modifying T-cells could treat melanoma according to two new studies conducted by researchers at the Clinical Research Division of the Fred Hutch Cancer ... Read more

June 30, 2016June 30, 2016

Melanoma Skin Check Partners Help Patients Identify New Cancers

News

A recent clinical trial proved that skin-check partners of melanoma patients can successfully assist with skin self-examinations by recognizing new melanomas and increasing early detection of the cancer. The study, “Early Detection of New ... Read more

May 24, 2016May 24, 2016

Pembrolizumab Thwarts Advanced Melanoma, Study Reports

News

In the largest study ever performed in patients with advanced melanoma, researchers showed that the immunotherapy medication pembrolizumab (Keytruda) put the cancer in regression with treatment effects lasting up to three ... Read more

April 28, 2016April 28, 2016

Nivolumab (Opdivo) Seen in Clinical Trial to Improve Long-Term Survival in Advanced Melanoma Patients

News

Bristol-Myers Squibb’s nivolumab (Opdivo) has shown a robust five-year overall survival (OS) rate of 34 percent in heavily pretreated patients with metastatic melanoma, who had not received prior ipilimumab (Yervoy) therapy. ... Read more

March 31, 2016March 31, 2016

Immunocore Recruits 1st Uveal Melanoma Patient in Phase I Trial of Biological Drug, IMCgp100

News

Immunocore announced it has recruited the first patient for its Phase I monotherapy clinical trial of IMCgp100, its lead product candidate to treat uveal melanoma. Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary ... Read more

February 2, 2016February 2, 2016

Philogen Launches Phase 3 Melanoma Clinical Trial

News

Philogen S.p.A. of Siena, Italy, recently launched a pivotal clinical trial in patients with stage 3B/C melanoma, after promising results from its Phase 2 trial of a novel immunotherapeutic combination treatment. Patients with stage ... Read more

January 14, 2016January 14, 2016

First Melanoma Patients Dosed in Trials of Investigational Drug PV-10

News

Provectus Biopharmaceuticals of Knoxville, Tenn., has confirmed the first dosage of PV-10 in two clinical trials to patients with both Stage 3 locally advanced cutaneous melanoma and Stage 4 metastatic melanoma. Both ... Read more

December 10, 2015December 10, 2015

Metastatic Melanoma Immunotherapy Shows Promise in Mice Study

News

Memgen LLC, a company that develops cancer immunotherapies, presented positive preclinical data for its main immuno-oncology drug, ISF35, during the 30th annual meeting of the Society of Immunotherapy of Cancer ... Read more

December 4, 2015December 3, 2015

Array, Pierre Fabre to Collaborate on New Melanoma Drugs

News

Array BioPharma Inc., based in Colorado, and Pierre Fabre of France have recently announced they will collaborate on the development and commercialization of novel oncology products for the treatment of melanoma and ... Read more

November 12, 2015November 12, 2015

Roche’s New Melanoma Drug, Cotellic, Gets FDA Approval

News

Roche recently announced that the U.S. Food and Drug Administration (FDA) approved Cotellic (cobimetinib) used in combination with Zelboraf (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive ... Read more

November 10, 2015November 12, 2015

New Metastatic Melanoma Treatment from Caladrius Shows Promise

News

Caladrius Biosciences, Inc., recently presented novel data at the 2015 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which took place in Baltimore, Maryland, Nov. 4-8, 2015. The clinical ... Read more

July 29, 2015July 29, 2015

Novel Clinical Trial for BRAFV600-Advanced Melanoma Initiates Patient Recruitment

News

The ECOG-ACRIN Cancer Research Group recently announced it will begin patient enrolment in its Phase III cancer clinical trial that will compare two differently acting treatments that have previously shown to be ... Read more

July 24, 2015July 24, 2015

Georgetown University Medical Center Physician to Lead National Melanoma Clinical Trial

News

A renowned Georgetown University Medical Center physician will lead a national clinical trial involving new treatments for melanoma. The trial will compare two groups of drugs known for their ... Read more

June 12, 2015June 12, 2015

Provectus Begins Patient Enrolment for Phase 3 Trial of PV-10 for Melanoma

News

Provectus Biopharmaceuticals, Inc. a biopharmaceutical company specializing in developing oncology and dermatology therapies, recently announced that a new Phase 3 international FDA comparative clinical study of PV-10 in melanoma treatment has ... Read more

Pin It on Pinterest